Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line - Concepedia

Concepedia

Publication | Closed Access

Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line

40

Citations

27

References

2020

Year

S. Eftekhari, Hamed Montazeri, Parastoo Tarighi

European Journal of Pharmacology

UrologyMedicinePharmacotherapySynergistic Anti-tumor EffectsAnti-cancer AgentCancer TreatmentProstatic DiseasePharmacology

References

	Year	Citations

Page 1